Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash & Equivalents (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Cash & Equivalents data on record, last reported at $737.1 million in Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 87.98% year-over-year to $737.1 million; the TTM value through Dec 2025 reached $737.1 million, up 87.98%, while the annual FY2025 figure was $737.1 million, 87.98% up from the prior year.
  • Cash & Equivalents reached $737.1 million in Q4 2025 per OCUL's latest filing, up from $344.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $737.1 million in Q4 2025 and bottomed at $66.6 million in Q2 2023.
  • Average Cash & Equivalents over 5 years is $264.2 million, with a median of $193.8 million recorded in 2021.
  • Peak YoY movement for Cash & Equivalents: plummeted 50.49% in 2023, then soared 590.16% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $164.2 million in 2021, then tumbled by 37.68% to $102.3 million in 2022, then soared by 91.4% to $195.8 million in 2023, then skyrocketed by 100.25% to $392.1 million in 2024, then surged by 87.98% to $737.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Equivalents were $737.1 million in Q4 2025, $344.8 million in Q3 2025, and $391.1 million in Q2 2025.